Tenofovir for the treatment of hepatitis B virus

Alice M. Jenh, Chloe L Thio, Paul Pham

Research output: Contribution to journalArticle

Abstract

Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults. Tenofovir has been available in the United States for the treatment of human immunodeficiency virus (HIV) since 2001. It blocks HBV replication in liver cells and is available as a once-daily oral formulation. The efficacy of tenofovir for the treatment of chronic HBV has been demonstrated to be superior to adefovir in randomized controlled trials, which led to its FDA approval for use in chronic HBV. Because of its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir should replace adefovir as a first-line monotherapy option in the treatment of HBV in monoinfected patients. In the HIV-HBV-coinfected population, tenofovir is already a preferred agent in combination with other anti-HBV agents (lamivudine or emtricitabine), which are cotreatments for HIV as well. In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir.

Original languageEnglish (US)
Pages (from-to)1212-1227
Number of pages16
JournalPharmacotherapy
Volume29
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Tenofovir
Hepatitis B virus
Chronic Hepatitis B
Lamivudine
HIV
United States Food and Drug Administration
Therapeutics
Drug Approval
Reverse Transcriptase Inhibitors
Virus Diseases
Virus Replication
Nucleosides

Keywords

  • Chronic hepatitis B virus
  • HBV
  • Nucleotide analog reverse transcriptase inhibitor
  • Tenofovir disoproxil fumarate

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Tenofovir for the treatment of hepatitis B virus. / Jenh, Alice M.; Thio, Chloe L; Pham, Paul.

In: Pharmacotherapy, Vol. 29, No. 10, 10.2009, p. 1212-1227.

Research output: Contribution to journalArticle

Jenh, Alice M. ; Thio, Chloe L ; Pham, Paul. / Tenofovir for the treatment of hepatitis B virus. In: Pharmacotherapy. 2009 ; Vol. 29, No. 10. pp. 1212-1227.
@article{8a48f710d99548d5baaff452c7ab7db5,
title = "Tenofovir for the treatment of hepatitis B virus",
abstract = "Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults. Tenofovir has been available in the United States for the treatment of human immunodeficiency virus (HIV) since 2001. It blocks HBV replication in liver cells and is available as a once-daily oral formulation. The efficacy of tenofovir for the treatment of chronic HBV has been demonstrated to be superior to adefovir in randomized controlled trials, which led to its FDA approval for use in chronic HBV. Because of its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir should replace adefovir as a first-line monotherapy option in the treatment of HBV in monoinfected patients. In the HIV-HBV-coinfected population, tenofovir is already a preferred agent in combination with other anti-HBV agents (lamivudine or emtricitabine), which are cotreatments for HIV as well. In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir.",
keywords = "Chronic hepatitis B virus, HBV, Nucleotide analog reverse transcriptase inhibitor, Tenofovir disoproxil fumarate",
author = "Jenh, {Alice M.} and Thio, {Chloe L} and Paul Pham",
year = "2009",
month = "10",
doi = "10.1592/phco.29.10.1212",
language = "English (US)",
volume = "29",
pages = "1212--1227",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Tenofovir for the treatment of hepatitis B virus

AU - Jenh, Alice M.

AU - Thio, Chloe L

AU - Pham, Paul

PY - 2009/10

Y1 - 2009/10

N2 - Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults. Tenofovir has been available in the United States for the treatment of human immunodeficiency virus (HIV) since 2001. It blocks HBV replication in liver cells and is available as a once-daily oral formulation. The efficacy of tenofovir for the treatment of chronic HBV has been demonstrated to be superior to adefovir in randomized controlled trials, which led to its FDA approval for use in chronic HBV. Because of its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir should replace adefovir as a first-line monotherapy option in the treatment of HBV in monoinfected patients. In the HIV-HBV-coinfected population, tenofovir is already a preferred agent in combination with other anti-HBV agents (lamivudine or emtricitabine), which are cotreatments for HIV as well. In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir.

AB - Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults. Tenofovir has been available in the United States for the treatment of human immunodeficiency virus (HIV) since 2001. It blocks HBV replication in liver cells and is available as a once-daily oral formulation. The efficacy of tenofovir for the treatment of chronic HBV has been demonstrated to be superior to adefovir in randomized controlled trials, which led to its FDA approval for use in chronic HBV. Because of its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir should replace adefovir as a first-line monotherapy option in the treatment of HBV in monoinfected patients. In the HIV-HBV-coinfected population, tenofovir is already a preferred agent in combination with other anti-HBV agents (lamivudine or emtricitabine), which are cotreatments for HIV as well. In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir.

KW - Chronic hepatitis B virus

KW - HBV

KW - Nucleotide analog reverse transcriptase inhibitor

KW - Tenofovir disoproxil fumarate

UR - http://www.scopus.com/inward/record.url?scp=70349658098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349658098&partnerID=8YFLogxK

U2 - 10.1592/phco.29.10.1212

DO - 10.1592/phco.29.10.1212

M3 - Article

C2 - 19792994

AN - SCOPUS:70349658098

VL - 29

SP - 1212

EP - 1227

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10

ER -